The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMS 2024 | Insights into SWIFT-Seq: how may this novel method benefit clinical practice?
In this video, Irene Ghobrial, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, briefly discusses SWIFT-Seq, a novel method which makes use of single-cell RNA sequencing of circulating tumor cells (CTCs) to better understand risk of progression in individuals with precursor conditions. This interview took place at the 21st International Myeloma Society (IMS) Annual Meeting, held in Rio de Janeiro, Brazil.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
